MassBiologics
MassBiologics, part of UMass Chan Medical School, is the only nonprofit, FDA-licensed manufacturer of vaccines and biologics in the United States. With over 100 years of experience, it is dedicated to improving public health through the research, development, and production of biologic products, including vaccines and monoclonal antibodies.
MassBiologics
460 Walk Hill Street, Boston, MA 02126
What We Do
MassBiologics provides a variety of development, analytical, and manufacturing services to assist collaborators or clients in drug development and manufacturing for clinical trials.
MassBiologics supports a variety of development project needs, taking projects from bench to bedside, including nonGMP monoclonal antibody and protein production.
MassBiologics performs cGMP manufacturing activities in its FDA licensed facility, ensuring safety and quality control for biologics production.
MassBiologics offers aseptic fill and finish services with configurations for both clinical and commercial production, utilizing advanced equipment for high-quality output.
MassBiologics maintains high standards of quality in cGMP projects, ensuring compliance with regulatory standards through rigorous quality control and assurance processes.
MassBiologics manufactures the Tetanus and Diphtheria Toxoids Adsorbed (Td) vaccine, which is distributed nationwide by Grifols USA.
Services
Show More (4)Application Area
Show More (5)Digital Health Technologies
Diagnostics
Show More (3)Medical Devices
Psychological and Cognitive Health and Performance
Show More (2)Battlefield Resuscitation
Show More (1)News & Updates
MassBiologics has partnered with SparingVision to manufacture gene therapy aimed at treating ocular diseases.
MassBiologics has entered into an agreement with PTC Therapeutics to manufacture biological investigational new drugs and commercial pharmaceutical products for use in humans.
Victor Ambros, a researcher at UMass Chan Medical School, was awarded the 2024 Nobel Prize for his discovery of microRNA, which plays a crucial role in gene regulation.
PTC Therapeutics announced that the European Commission has granted marketing authorization for Upstaza, a gene therapy developed in partnership with MassBiologics.